BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


View Clinical Trials from BioPharm Insight

The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.

 Key Statistics

Ownership: Public

Web Site: The Medicines Company
Employees: 500+
Symbol: MDCO


UCB, Inc.  Contract manufacturing of Bivalirudin peptide active ingredient

Alnylam Pharmaceuticals 

 Company News
The Medicines Company (MDCO) Receives CHMP Positive Opinions For Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV™ (oritavancin) And RAPLIXA™ (sealant powder) 1/23/2015 9:10:02 AM
The Medicines Company (MDCO) Prices $350 Million Of Convertible Notes 1/8/2015 1:56:25 PM
The Medicines Company (MDCO) Announces Intention To Offer $300 Million Of Convertible Notes 1/7/2015 10:50:18 AM
The Medicines Company (MDCO) To Participate In 33rd Annual J.P. Morgan Healthcare Conference 1/6/2015 11:22:33 AM
The Medicines Company (MDCO) Reaches $55 Million Licensing Partnership With SciClone Pharmaceuticals, Inc. (SCLN) 12/18/2014 9:16:07 AM
Alnylam Pharmaceuticals (ALNY) And The Medicines Company (MDCO) Announce Initiation Of Phase 1 Clinical Trial For ALN-Pcssc, A Subcutaneously Administered Investigational Rnai Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia 12/11/2014 9:11:56 AM
The Medicines Company (MDCO) To Participate In Oppenheimer 25th Annual Healthcare Conference 12/8/2014 9:52:05 AM
The Medicines Company (MDCO) Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients 11/17/2014 11:50:11 AM
The Medicines Company (MDCO) To Present New Data On Investigational Lipid-Modifying Agent MDCO-216 And Investigational Antiplatelet Agent Cangrelor At 2014 American Heart Association Annual Scientific Sessions In Chicago 11/14/2014 9:40:57 AM
The Medicines Company (MDCO) To Participate In Credit Suisse Healthcare Conference 11/11/2014 10:39:31 AM